Clément O, Siauve N, Cuénod C A, Vuillemin-Bodaghi V, Leconte I, Frija G
Service de Radiologie, Hôpital Boucicaut-Laënnec, Paris, France.
J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. doi: 10.1097/00004728-199911001-00007.
New contrast agents for magnetic resonance imaging are continually being developed by pharmaceutical companies in order to better image the liver. These agents can be divided into hepatobiliary agents directed to the hepatocytes and nanoparticulate agents directed to the reticulo-endothelial system. After intravenous injection, all these agents concentrate in the liver and induce profound changes in signal intensity. Particulate agents induce predominantly a darkening of the liver parenchyma, while hepatobiliary agents induce a brightening. In both cases, liver-lesion conspicuity is enhanced, leading to a better visualization of the lesion. After a brief description of the principal characteristics of the agents, this paper will attempt to summarize the utility of these agents for the detection and characterization of focal liver disease.
制药公司不断研发用于磁共振成像的新型造影剂，以便更好地对肝脏进行成像。这些造影剂可分为针对肝细胞的肝胆造影剂和针对网状内皮系统的纳米颗粒造影剂。静脉注射后，所有这些造影剂都会在肝脏中聚集，并引起信号强度的显著变化。颗粒造影剂主要导致肝实质变暗，而肝胆造影剂则导致肝实质变亮。在这两种情况下，肝脏病变的显影度均会提高，从而使病变能被更好地观察到。在简要描述了这些造影剂的主要特性之后，本文将尝试总结这些造影剂在检测和鉴别局灶性肝病方面的效用。
